Noema is a Swiss-based company targeting orphan neurological disorders characterized by imbalanced neuronal networks. The company is developing four mid-clinical-stage therapeutic products in-licensed from Roche and with strong safety packages.

Biopharmaceuticals

Antoine Papiernik

Antoine Papiernik is a Managing Partner at Sofinnova Partners, which he joined in 1997. Antoine has been an initial investor and active board member in public companies like Actelion, ProQR, Shockwave Medical,  NovusPharma (then sold to CTI), Movetis (then sold to Shire), Mainstay, Pixium Vision and...